Wilson-Robles, H. M.
Bygott, T.
Kelly, T. K.
Miller, T. M.
Miller, P.
Matsushita, M.
Terrell, J.
Bougoussa, M.
Butera, T.
Funding for this research was provided by:
Volition Veterinary Diagnostic Development, LLC
Article History
Received: 21 December 2021
Accepted: 19 August 2022
First Online: 31 August 2022
Declarations
:
: All animal studies were approved by the Texas A&M University Animal Care and Use Committee (AUP #2017–0350). Client-owned animals were evaluated with the informed consent of the owner (AUP #2019–0211).
: Not applicable.
: JT, TK, MB and TB are employees of Volition Diagnostics UK Ltd & Volition America, which have patents covering Nu.Q technology and are developers of Nu.QTM assays. Volition Veterinary is a joint venture between Belgian Volition and Texas A&M University. HWR is a paid consultant of Volition Veterinary. TM, MM and JJ have no conflicts of interest to declare. Additional salary support for TM was provided by the Fred and Vola Palmer Chair in Comparative Oncology held by HWR. The Palmers did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support for the authors’ salaries (T.M.). This does not alter our adherence to BMC policies on sharing data and materials.